New Treatments for Systemic Sclerosis aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z

• New Treatments for Systemic Sclerosis | RheumNow

Camels and psoriatic arthritis - a new treatment link https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX

• Camels and psoriatic arthritis - a new treatment link | RheumNow

EULAR 2024 – Day 4 Report The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action. https://t.co/1lQcu1beOm https://t.co/QHMcFzaG48

• EULAR 2024 – Day 4 Report | RheumNow

We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria. https://t.co/mrr5MWxeJz https://t.co/0FMLaAxaWV

• We've Got to Talk about CAR T cells | RheumNow

Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria. https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd

• Select your GCA Therapy | RheumNow

Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria. https://t.co/Nc0XymI24l https://t.co/69qdLh63ct

• Predicting Palindromic Prognosis | RheumNow

Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C

• Giant Cell Arteritis and Polymyalgia Rheumatica Update | RheumNow

Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria. https://t.co/mv9DeZ9cez https://t.co/1OpT3MomO8

• Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA | RheumNow

Update on low-dose glucocorticoids in SLE GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions. https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W

• Update on low-dose glucocorticoids in SLE | RheumNow

Achieving drug-free remission in axSpA In early axSpA, over 60% achieved sustained inactive disease. Male, non-smokers, low BASDAI scores had higher remission rates. Drug-free remission remains challenging. https://t.co/Yv8a8C1hc9 https://t.co/JaYvfGry4P

• Achieving drug-free remission in axSpA | RheumNow

POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa Retrospective study in French THIN database Diagnostic delay remains common Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain #EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw